Literature DB >> 21795358

Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge.

Eiko Matsuo1, Cristina C P Celma, Mark Boyce, Cyril Viarouge, Corinne Sailleau, Eric Dubois, Emmanuel Bréard, Richard Thiéry, Stéphan Zientara, Polly Roy.   

Abstract

The reverse genetics technology for bluetongue virus (BTV) has been used in combination with complementing cell lines to recover defective BTV-1 mutants. To generate a potential disabled infectious single cycle (DISC) vaccine strain, we used a reverse genetics system to rescue defective virus strains with large deletions in an essential BTV gene that encodes the VP6 protein (segment S9) of the internal core. Four VP6-deficient BTV-1 mutants were generated by using a complementing cell line that provided the VP6 protein in trans. Characterization of the growth properties of mutant viruses showed that each mutant has the necessary characteristics for a potential vaccine strain: (i) viral protein expression in noncomplementing mammalian cells, (ii) no infectious virus generated in noncomplementing cells, and (iii) efficient replication in the complementing VP6 cell line. Further, a defective BTV-8 strain was made by reassorting the two RNA segments that encode the two outer capsid proteins (VP2 and VP5) of a highly pathogenic BTV-8 with the remaining eight RNA segments of one of the BTV-1 DISC viruses. The protective capabilities of BTV-1 and BTV-8 DISC viruses were assessed in sheep by challenge with specific virulent strains using several assay systems. The data obtained from these studies demonstrated that the DISC viruses are highly protective and could offer a promising alternative to the currently available attenuated and killed virus vaccines and are also compliant as DIVA (differentiating infected from vaccinated animals) vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795358      PMCID: PMC3196398          DOI: 10.1128/JVI.05412-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  Prospects for improved bluetongue vaccines.

Authors:  Polly Roy; Mark Boyce; Robert Noad
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

2.  Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep.

Authors:  H Huismans; N T van der Walt; M Cloete; B J Erasmus
Journal:  Virology       Date:  1987-03       Impact factor: 3.616

3.  Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments.

Authors:  J F Toussaint; C Sailleau; E Breard; S Zientara; K De Clercq
Journal:  J Virol Methods       Date:  2006-12-28       Impact factor: 2.014

4.  Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.

Authors:  Josh D Boone; Udeni B Balasuriya; Kemal Karaca; Jean-Christophe Audonnet; Jiansheng Yao; Ling He; Robert Nordgren; Federica Monaco; Giovanni Savini; Ian A Gardner; N James Maclachlan
Journal:  Vaccine       Date:  2006-09-05       Impact factor: 3.641

Review 5.  Orbivirus structure and assembly.

Authors:  P Roy
Journal:  Virology       Date:  1996-02-01       Impact factor: 3.616

6.  Possible routes of introduction of bluetongue virus serotype 8 into the epicentre of the 2006 epidemic in north-western Europe.

Authors:  K Mintiens; E Méroc; P S Mellor; C Staubach; G Gerbier; A R W Elbers; G Hendrickx; K De Clercq
Journal:  Prev Vet Med       Date:  2008-07-29       Impact factor: 2.670

7.  Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus.

Authors:  M Stewart; Y Bhatia; T N Athmaran; R Noad; C Gastaldi; E Dubois; P Russo; R Thiéry; C Sailleau; E Bréard; S Zientara; P Roy
Journal:  Vaccine       Date:  2009-11-01       Impact factor: 3.641

Review 8.  Functional mapping of bluetongue virus proteins and their interactions with host proteins during virus replication.

Authors:  Polly Roy
Journal:  Cell Biochem Biophys       Date:  2008-02-26       Impact factor: 2.194

9.  Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants.

Authors:  Aurélie Perrin; Emmanuel Albina; Emmanuel Bréard; Corinne Sailleau; Sylvie Promé; Colette Grillet; Olivier Kwiatek; Pierre Russo; Richard Thiéry; Stephan Zientara; Catherine Cêtre-Sossah
Journal:  Vaccine       Date:  2007-07-16       Impact factor: 3.641

10.  In vitro transcription and translation of bluetongue virus mRNA.

Authors:  A A Van Dijk; H Huismans
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

View more
  35 in total

1.  The 13th International Double-Stranded RNA Virus Symposium, Houffalize, Belgium, 24 to 28 September 2018.

Authors:  Ulrich Desselberger
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  A protective bivalent vaccine against Rift Valley fever and bluetongue.

Authors:  Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Julio Benavides; Aitor Nogales; Rafael Blasco; Alejandro Brun; Javier Ortego
Journal:  NPJ Vaccines       Date:  2020-07-30       Impact factor: 7.344

Review 3.  Comparative analysis of Reoviridae reverse genetics methods.

Authors:  Shane D Trask; Karl W Boehme; Terence S Dermody; John T Patton
Journal:  Methods       Date:  2012-06-08       Impact factor: 3.608

4.  Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep.

Authors:  Cristina C P Celma; Mark Boyce; Piet A van Rijn; Michael Eschbaumer; Kerstin Wernike; Bernd Hoffmann; Martin Beer; Andy Haegeman; Kris De Clercq; Polly Roy
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

5.  An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.

Authors:  Mani Saminathan; Karam Pal Singh; Jaynudin Hajibhai Khorajiya; Murali Dinesh; Sobharani Vineetha; Madhulina Maity; At Faslu Rahman; Jyoti Misri; Yashpal Singh Malik; Vivek Kumar Gupta; Raj Kumar Singh; Kuldeep Dhama
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

Review 6.  The molecular biology of Bluetongue virus replication.

Authors:  Avnish Patel; Polly Roy
Journal:  Virus Res       Date:  2013-12-25       Impact factor: 3.303

7.  Dendritic cell subtypes from lymph nodes and blood show contrasted gene expression programs upon Bluetongue virus infection.

Authors:  Suzana Ruscanu; Luc Jouneau; Céline Urien; Mickael Bourge; Jérôme Lecardonnel; Marco Moroldo; Benoit Loup; Marc Dalod; Jamila Elhmouzi-Younes; Claudia Bevilacqua; Jayne Hope; Damien Vitour; Stéphan Zientara; Gilles Meyer; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

8.  Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.

Authors:  Edward Sullivan; Sylvie Lecollinet; Adeline Kerviel; Erika Hue; Stéphane Pronost; Cécile Beck; Marine Dumarest; Stephan Zientara; Polly Roy
Journal:  Vaccine       Date:  2021-05-03       Impact factor: 3.641

9.  Minimum requirements for bluetongue virus primary replication in vivo.

Authors:  Eiko Matsuo; Polly Roy
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

10.  Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.

Authors:  René G P van Gennip; Sandra G P van de Water; Mieke Maris-Veldhuis; Piet A van Rijn
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.